Pharmaceuticals & Biotech Sector Weekly (2026-07-21)

Report date: 2026-07-21 | Data window: real-time X (Twitter) search over the past 168 hours (2026-07-14 to 07-21), industry signals over 14 days (since 07-07) | Prices: US as of Monday 07-20 close, A-share/HK as of 07-21 close (Tencent Securities snapshots) | Sources: grok-x x_search (broad sweep + biotech KOLs + core newswire accounts + biotech trade media + China media) + eastmoney price verification. Public social-media digest for informational and educational purposes only; not investment advice.

The week's dominant theme rotated from the prior fortnight's M&A wave to the year of the oral pill: the FDA approved Merck's first-in-class oral PCSK9 cholesterol drug, the WSJ declared Eli Lilly is "losing" the weight-loss pill launch battle to Novo Nordisk, and on the China side Hengrui's dual GLP-1/GIP agonist posted positive Phase 3 data while China's first domestic oral small-molecule GLP-1 was filed for approval. Sentiment skewed bullish (~70% of broad-sweep posts positive, no notable bear posts), yet US large-cap pharma sold off Monday (XBI -2.15%, LLY -2.73%, MRK -2.43%) — a notable divergence between newsflow and tape. A-share innovative pharma/CXO extended their rebound (Joinn Labs +4.51%, WuXi AppTec +1.8%).

1. Key Events

• FDA approved Merck's Lipfendra, the first oral PCSK9 cholesterol pill — "a pill version of powerful cholesterol medication that Wall Street analysts have said could generate billions of annual sales"; MRK closed Monday at $124.40 (-2.43%, in line with the sector pullback). @business @FirstSquawk @FierceBiotech 𝕏¹ 𝕏² 𝕏³
• Eli Lilly reportedly in talks to acquire psychedelics drugmaker AtaiBeckley ($ATAI): per @zerohedge citing people familiar, ATAI leapt as much as 34% on the day (07-16); it closed Monday at $7.19. Still a rumor, unconfirmed by either party. 𝕏
• WSJ: Lilly is losing the weight-loss pill launch battle — "The launch of weight-loss pills is the hottest battle in pharma. So far, Eli Lilly is losing to rival Novo Nordisk." KOLs cited prescription data showing Novo's oral Wegovy has captured ~89% of the oral GLP-1 market. LLY closed Monday at $1,146.90 (-2.73%); NVO ADR at $49.61 (-1.41%). @WSJ @yaireinhorn 𝕏¹ 𝕏²
• Hengrui's dual GLP-1/GIP agonist ribupatide (HRS9531) hit in Phase 3: HbA1c reduction of 2.37%/2.67% vs 0.36% for placebo; China NDA filed for T2D, weight-management NDA already under review; ex-Greater-China rights licensed to Kailera ($KLRA). @chuminhua432 𝕏
• China's first domestic oral small-molecule GLP-1R agonist filed for approval: Vincentage Pharma's VCT220 (weight loss -12.2%/-12.4% vs -1.3% placebo); ex-China global rights licensed to Corxel. @chuminhua432 𝕏
• FDA approved Celcuity's ($CELC) breast cancer drug — a key regulatory milestone for the small-cap biotech. @Reuters 𝕏
• Big-pharma pipeline pruning: GSK axed a key cough drug candidate after Phase 3 data; J&J scrapped an eye-disease gene therapy after a Phase 2b readout. GSK ADR -3.32% Monday. @FierceBiotech 𝕏¹ 𝕏²
• Immix ($IMMX)/Atossa executive scandal: a most-wanted fugitive was revealed to have been secretly working as a biotech executive (formerly Immix's chief physician); IMMX plunged 14.15% Monday to $8.80. @adamfeuerstein @bradloncar 𝕏¹ 𝕏²

2. Institutional & Media Coverage

Factual reporting

• @business / @FirstSquawk / @FierceBiotech (fact, consolidated): FDA approved Merck's oral cholesterol pill Lipfendra (PCSK9 inhibitor for adults with hypercholesterolemia) — the first oral entrant in the PCSK9 class, framed as both substitution for and expansion of the injectable market held by Amgen's Repatha and Regeneron's Praluent. 𝕏¹ 𝕏²
• @zerohedge (fact of the report; deal itself a rumor): Lilly in talks to acquire AtaiBeckley — if consummated, big pharma's first major move into psychedelic neuropsychiatry. 𝕏
• @Reuters (fact): "US FDA approves Celcuity's breast cancer drug" (posted twice). 𝕏
• @FierceBiotech (fact, multiple items): Kolon TissueGene's cell-based gene therapy missed Phase 3 co-primary endpoints; Takeda's zasocitinib Phase 3 update — "the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients"; InnoCare's TYK2 inhibitor won a Phase 2 vitiligo trial, "racing Takeda"; Scribe Therapeutics filed for a $96M IPO; Bristol Myers Squibb touted a strengthened Nvidia collaboration to build "the most powerful AI factory in life sciences." 𝕏¹ 𝕏² 𝕏³ 𝕏⁴
• @adamfeuerstein (STAT, fact): "A most-wanted fugitive appears to have been secretly working as a biotech executive" — involving Atossa ($ATOS) and Immix ($IMMX); @bradloncar blasted Immix's governance: "It's crazy that Immix called his firing an immaterial event in their 8K… Sounds like they had a con artist acting as the company's chief physician and that's immaterial?" 𝕏¹ 𝕏²

Opinion / ratings

• @WSJ (report with a verdict): weight-loss pills are pharma's "hottest battle," and Lilly is currently losing — the week's main source of LLY bear narrative. 𝕏
• @adamfeuerstein (opinion, critical): "In the GLP-1 boom times, whose interests do telehealth providers prioritize — patients seeking drugs, or the makers of obesity drugs like $LLY and $NVO?" citing an internal "culture to produce rather than be thorough" — a compliance question mark over the GLP-1 telehealth channel (LifeMD et al.). 𝕏
• @cnfinancewatch (opinion, bullish CXO): mapped the CRO value chain, calling WuXi AppTec the "global CXO platform leader" with in-house primate facilities buffering rising monkey costs; CROs benefit in an innovative-drug upcycle. 𝕏

3. KOL Bull & Bear Views

GLP-1 / Obesity ($NVO vs $LLY)

Bullish (mostly on NVO)

• @yaireinhorn (≈50 likes / 88k views, highest engagement this section): "After a long period in which $LLY seemed to gain the upper hand… the tables have turned and $NVO has finally found a new path to the GLP-1 throne via its new oral Wegovy pill… secured an 89% market share. The GLP-1 battle of titans is far from over! $XBI" 𝕏
• @jonaskkaberg1 (≈10 likes): "Oral GLP-1 will be a larger market than injections in the future. $NVO is winning that market in US, and has a much stronger position than Eli Lilly outside US." 𝕏
• @pulseandprofit (low engagement): "If oral GLP-1s meaningfully expand the total addressable market… $NVO current valuation could look far too pessimistic while investors remain focused on $LLY" — NVO's ADR trades at only ~11.8x trailing earnings (Tencent Securities), making the valuation gap the core bull case. 𝕏

Bearish / Cautious (mostly on LLY)

• @Arturraposo1R (low engagement): "$LLY was priced in as the winner of GLP-1 pills. And $NVO came in to scoop 90% of the current market… justifying my choice of $NVO." — LLY is valued (~40.7x TTM) as the presumptive oral winner while actual share went to NVO, an implicit valuation-risk flag. 𝕏
• @adamfeuerstein (≈20 likes): compliance questions over the GLP-1 telehealth prescribing channel ($LFMD et al., see Section 2) — a potential tail risk for the ecosystem. 𝕏

China innovative pharma / CXO

Bullish

• @gupiaoyzz (≈14 likes / 10 reposts): "Three core engines: 1️⃣ earnings inflection — innovative-drug interim profits starting to materialize; 2️⃣ policy tailwind — essential drug list expansion; 3️⃣ license-out as hard currency — a necessity for MNCs. Focus: innovators (Hengrui/BeiGene/Akeso) and the CXO chain (WuXi/Tigermed/Pharmaron)." (translated) 𝕏
• @cnfinancewatch (≈22 likes): "The innovative-drug sector has seen more gains than losses over the past month; since last week I've held that it has entered a rebound trend" (translated); a separate post flagged CRO catalysts: "Joinn Labs guided profits up 885%; lab monkey prices up to RMB 180-200k; essential drug list expansion." 𝕏¹ 𝕏²
• @chuminhua432 (≈3 likes, data posts): back-to-back hard-data posts on Hengrui's ribupatide Phase 3 win and VCT220's NDA filing (see Key Events) — the week's primary information source for China's GLP-1 narrative. 𝕏

Other

• @bradloncar (≈85 likes / 13k views, governance criticism): slammed Immix's disclosure (see Section 2); separately promoted this week's US Science Summit in Boston ("getting science back on track in the United States") — constructive on the industry's public-engagement front. 𝕏
• @fling_dot_baby (neutral): "Merck kills the needle. FDA approves the first oral cholesterol pill… Long or short $MRK?" — retail still undecided post-approval. 𝕏

4. Buzz & Sentiment Shifts

• GLP-1 / obesity (hottest topic): buzz rose markedly and was the only theme spanning both the US and China conversations. Sentiment split structurally: clearly warmer on NVO (oral Wegovy share data + cheap valuation), cooler on LLY (WSJ's "losing" verdict + rich multiple), roughly 6:3:1 bull/bear/neutral. A clear reversal from the 07-07 weekly, when the highest-engagement post was bearish NVO on "single-product dependence and a weak pipeline"; this week the narrative flipped to "NVO retakes the oral throne."
• US biotech overall ($XBI): ~71% of broad-sweep posts leaned bullish with no notable bear posts, yet the tape disagreed — XBI fell 2.15% Monday with large-cap pharma broadly lower; the "warm newsflow, weak price action" divergence bears watching. The prior fortnight's M&A theme cooled visibly, leaving only the Lilly-Atai rumor; attention rotated to oral-dosage innovation and single-stock events (the Immix scandal).
• China innovative pharma / CXO (A-share/HK): buzz kept climbing week over week, with sentiment bullish and shifting from narrative to earnings delivery (interim profits, Joinn's +885% guidance, routine license-outs). The tape outperformed US peers: on 07-21 WuXi AppTec +1.8% (close RMB 126.45), Joinn Labs +4.51%, InnoCare +1.47%, BeiGene HK +0.78%; Hengrui, despite its Phase 3 win, closed down 1.15% at RMB 54.93 — good news failing to lift the stock on the day suggests the move was partly priced in.

5. First-hand Industry Signals (Last 14 Days)

Times are US Eastern (ET); only concrete industry actions (named actor, action, date) are included.

Key interpretations

• Merck's oral PCSK9 approval is the first landing of the injectable-to-oral shift in lipid lowering. For Merck it is one of the most important growth drivers ahead of the Keytruda patent cliff (sell-side sees multi-billion-dollar peak sales); for Amgen (Repatha) and Regeneron (Praluent) it is direct substitution pressure; for the industry it validates the oral macrocyclic/small-molecule replacement path — rhyming with this week's oral GLP-1 battle. Notably, the approval did not hold up the stock: MRK still fell 2.43% Monday with the sector.
• Hengrui's HRS9531 Phase 3 win + VCT220 filing — a China GLP-1 double. Hengrui's dual-agonist data (HbA1c cuts of 2.4-2.7 points) numerically benchmark against Lilly's tirzepatide class, and the ex-China rights sit with Kailera ($KLRA), so the readout directly accretes milestone and royalty value; VCT220 claims the "first domestic oral small-molecule GLP-1 filing" position. Both reinforce the "China data for global deal value" thesis, with the CXO chain (WuXi AppTec, Joinn) the higher-certainty indirect beneficiary — indeed CXOs outperformed the innovators themselves this week (Hengrui closed down on its own good news, suggesting partial price-in).
• Lilly–AtaiBeckley (rumor): if real, it would be big pharma's first substantive bet on psychedelic neuropsychiatry and an M&A anchor for a chronically discounted subsector. For now it remains a press report citing people familiar; after the 34% intraday spike on the news day, ATAI closed Monday at $7.19 (-0.42%) — the market is pricing deal probability conservatively.

Disclaimer: This report aggregates public information from X. Quoted posts do not represent the platform's views and their accuracy and completeness are not guaranteed; stock prices are per exchange closing data. This report does not constitute an offer to buy or sell any security or personalized investment advice. Investing involves risk.